WO2022004669A1 - Composition à appliquer sur la peau pour augmenter l'expression de ccn1 et ccn2 - Google Patents

Composition à appliquer sur la peau pour augmenter l'expression de ccn1 et ccn2 Download PDF

Info

Publication number
WO2022004669A1
WO2022004669A1 PCT/JP2021/024386 JP2021024386W WO2022004669A1 WO 2022004669 A1 WO2022004669 A1 WO 2022004669A1 JP 2021024386 W JP2021024386 W JP 2021024386W WO 2022004669 A1 WO2022004669 A1 WO 2022004669A1
Authority
WO
WIPO (PCT)
Prior art keywords
less
skin
extract
ccn1
ccn2
Prior art date
Application number
PCT/JP2021/024386
Other languages
English (en)
Japanese (ja)
Inventor
徹 中西
勤 山崎
隆昭 佐伯
Original Assignee
徹 中西
勤 山崎
隆昭 佐伯
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 徹 中西, 勤 山崎, 隆昭 佐伯 filed Critical 徹 中西
Publication of WO2022004669A1 publication Critical patent/WO2022004669A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]

Definitions

  • the present disclosure relates to a composition for skin application to increase the expression of CCN1 and CCN2.
  • the skin is composed of the epidermis, dermis and subcutaneous tissue from the outermost layer.
  • the epidermis plays a role in protecting the body from the external environment and ensuring its healthy condition.
  • the epidermis also plays a role in preventing the skin from drying out by suppressing the invasion of microorganisms and chemical substances and preventing the evaporation of water.
  • the dermis is composed of fibroblasts, tissue spheres / macrophages, mast cells, and plasma cells.
  • Fibroblasts are cells that produce collagen, elastin, hyaluronic acid, etc., and play a role in forming the dermis structure with collagen as a fiber bundle. Fibroblasts also play a role in migrating to the injured area when the skin tissue is damaged and initiating the production of extracellular matrix such as collagen. Due to these roles, fibroblasts play an important role in the process of wound healing.
  • Fibroblasts also have reduced proliferative capacity due to the effects of ultraviolet rays, desiccation, stress, and aging. Therefore, if the proliferative ability of fibroblasts is affected, it may cause skin aging such as a decrease in skin elasticity, or the rate of wound healing may be slowed down.
  • Patent Document 1 Studies for activating the proliferation of fibroblasts have been reported.
  • the present disclosure is intended to provide a novel composition for novel skin applications.
  • composition according to Item 2 which is used for promoting hair growth by promoting differentiation into cells or promoting proliferation of hair follicle stem cells and / or hair papilla cells.
  • Item 4 Item 6.
  • Item 5 Item 6.
  • Less than 10% alcohol extract of the butterfly bean is less than 10% ethanol extract of Pandan, and less than 10% alcohol extract of Pandan is less than 10% ethanol extract of Pandan.
  • Item 2. The composition according to any one of Items 1 to 3.
  • a bar graph showing the expression ratio of CCN1 by the water extract A bar graph showing the expression ratio of CCN1 with 70% ethanol extract.
  • a bar graph showing the expression ratio of CCN2 by the water extract A bar graph showing the expression ratio of CCN2 with 70% ethanol extract.
  • Clitoria ternatea L is a leguminous plant belonging to the genus C. ternatea of the genus Clitoria.
  • Clitoria ternatea can be cultivated and harvested, for example, by known methods, or is commercially available.
  • the Clitoria ternatea may be at least one site selected from the group consisting of flowers, leaves, stems, and roots, preferably one or both of the flowers and leaves, more preferably. Is a flower.
  • the weight of Clitoria ternatea is the weight of the dried form.
  • the water extract of Clitoria ternatea can be obtained, for example, by mixing crushed Clitoria ternatea and water, and separating and removing the solid matter from the obtained mixture by a separation method such as centrifugation or filtration.
  • the water extract of Clitoria ternatea (preferably dried flower) is obtained by mixing the pulverized C. elegans and 10 times the weight of water of the pulverized product, and the resulting mixed solution is 20 at room temperature. It can be obtained by separating and removing the solid matter from the mixed solution by a separation method such as centrifugation or filtration after leaving it for a minute.
  • the water extract of Clitoria ternatea may be liquid or solid.
  • the water extract of Clitoria ternatea (solid) can be prepared, for example, by freeze-drying the water extract of Clitoria ternatea (liquid).
  • the ethanol extract of less than 10% of Clitoria ternatea for example, a pulverized C. elegans and an aqueous ethanol solution of less than 10% w / w are mixed, and a solid substance is separated from the obtained mixed solution by a separation method such as centrifugation or filtration. It can be obtained by separation and removal.
  • the ethanol extract of less than 10% of Clitoria ternatea is a pulverized product of Clitoria ternatea (preferably dried flower) and an aqueous ethanol solution of less than 10% w / w, which is 10 times the weight of the pulverized product.
  • the ethanol extract of less than 10% w / w of Clitoria ternatea may be liquid or solid.
  • the ethanol extract (solid) of less than 10% w / w of Clitoria ternatea can be prepared, for example, by freeze-drying the ethanol extract (liquid) of less than 10% w / w of Clitoria ternatea.
  • the ethanol extract (liquid) of less than 10% w / w of Clitoria ternatea is, for example, a liquid obtained by solidifying the ethanol extract (liquid) of less than 10% w / w by freeze-drying and dissolving the solid in water. May be.
  • Ethanol extract of Clitoria ternatea is, for example, ethanol of less than 8% w / w, ethanol of less than 5% w / w, ethanol of less than 3% w / w, or ethanol of less than 1% w / w, and crushed C. elegans. It may be prepared by mixing with a substance and separating and removing the solid substance from the obtained mixed solution.
  • Pandanaceae is a monocotyledonous plant belonging to the genus Pandanaceae of the Pandanaceae family, and is also called panda leaf. Pandanaceae can be cultivated and harvested, for example, by known methods, or are commercially available. In one embodiment, Pandanaceae may be at least one site selected from the group consisting of leaves, stems, and roots, preferably one or both of the leaves and stems, more preferably. It is a leaf. The weight of Pandanaceae is the weight of the dried form.
  • the water extract of Pandanaceae can be obtained, for example, by mixing pulverized Pandanaceae with water and separating and removing the solid matter from the obtained mixed solution by a separation method such as centrifugation or filtration. ..
  • the water extract of Pandan (preferably dried leaves) is prepared by mixing a pulverized product of Pandan and 10 times the weight of water of the crushed product, and the resulting mixed solution is brought to room temperature. It can be obtained by separating and removing the solid matter from the mixed solution by a separation method such as centrifugation or filtration after leaving it for 20 minutes.
  • the water extract of Pandanaceae may be liquid or solid.
  • the water extract (solid) of Pandanaceae can be prepared, for example, by freeze-drying the water extract (liquid) of Pandanaceae.
  • the ethanol extract of less than 10% of Pandanaceae is obtained by mixing, for example, a pulverized product of Pandanaceae and an aqueous ethanol solution of less than 10% w / w, and solidifying the obtained mixed solution by a separation method such as centrifugation or filtration. It can be obtained by separating and removing objects.
  • the ethanol extract of less than 10% of Pandan is a pulverized product of Pandan (preferably dried leaves) and an aqueous ethanol solution of less than 10% w / w, which is 10 times the weight of the pulverized product.
  • the ethanol extract of Pandanaceae less than 10% w / w may be liquid or solid.
  • An ethanol extract (solid) of less than 10% w / w of Pandanaceae can be prepared, for example, an ethanol extract (liquid) of less than 10% w / w of Pandanaceae by freeze-drying.
  • the ethanol extract (liquid) of less than 10% w / w of Pandan for example, the ethanol extract (liquid) of less than 10% w / w was solidified by freeze-drying or the like, and the solid was dissolved in water. It may be a liquid.
  • Ethanol extracts of Pandan include, for example, ethanol of less than 8% w / w, ethanol of less than 5% w / w, ethanol of less than 3% w / w, or ethanol of less than 1% w / w, and Pandan. It may be prepared by mixing with the pulverized product of No. 1 and separating the solid substance from the obtained mixed solution.
  • Alcohol means a substance in which the hydrogen atom of a hydrocarbon is replaced with a hydroxy group.
  • the alcohol may be, for example, a monohydric alcohol having 1 to 5 carbon atoms (eg, ethanol, methanol, propanol and isopropanol), or a polyhydric alcohol having 2 to 5 carbon atoms (eg, glycerin, isopropylene glycol, propylene glycol and 1). , 3-Butylene glycol).
  • the alcohol is a monohydric alcohol having 1 to 5 carbon atoms, preferably one selected from the group consisting of ethanol, methanol, propanol and isopropanol, or a mixture thereof.
  • the alcohol is ethanol.
  • composition for skin application may be in a form applicable to the skin, and may be a solution system, an emulsifying system, a powder system, a gel system, an ointment system, a cream, a mist, an aerosol, a water-oil two-layer system, or water.
  • -Oil-powder may be a three-layer system.
  • the composition for skin application is, for example, a water extract of butterfly bean or an alcohol extract of less than 10%, and either or both of a water extract of Pandan or an alcohol extract of less than 10%.
  • composition for skin application may further contain a carrier or excipient applicable to the skin and, if necessary, a suitable additive as appropriate.
  • the composition for skin application can be prepared by a known method.
  • the composition for skin application is applied to the skin with either or both of a water extract of Clitoria ternatea or an alcohol extract of less than 10% and a water extract of Pandan or an alcohol extract of less than 10%. It can be prepared by mixing with a possible carrier or excipient.
  • CCN1 is a protein belonging to the CCN family, also known as Cysteinerich 61 (Cyr61). CCN1 is involved in cell proliferation, cell motility, cell differentiation, and cell aging through interaction with cell surface integrin receptors and heparan sulfate proteoglycans. The amino acid sequence and nucleic acid sequence of CCN1 are known.
  • CCN2 is a protein belonging to the CCN family, also known as connective tissue growth factor (CTGF).
  • CCN2 is involved in promoting fibroblast proliferation, promoting extracellular air mass production, promoting connective tissue proliferation, chondrocyte proliferation, promoting cell differentiation, wound healing, and fibrotic diseases.
  • the amino acid and nucleic acid sequences of CCN2 are known.
  • “Increased expression” of CCN1 and CCN2 means that the expression level of CCN1 and the expression level of CCN2 when the composition according to the present disclosure is added to cultured human skin fibroblasts is the addition of the composition according to the present disclosure. It may be increased by at least 20%, 30%, 40%, or 50% as compared with the expression level of CCN1 and the expression level of CCN2 when not used.
  • the expression level of CCN1 and CCN2 means the amount of RNA in cultured human fibroblasts corresponding to CCN1 or CCN2. The amount of RNA can be measured by RT-PCR as described in the examples herein.
  • Preventing skin aging means that the elasticity of the skin is maintained or improved.
  • the expression of CCN1 and CCN2 is increased, the differentiation of epidermal stem cells into epidermal keratinocytes is promoted, the proliferation of epidermal stem cells and / or epidermal keratinocytes is promoted, and the proliferation of dermal stem cells and / Alternatively, it can be achieved by promoting the differentiation into fibroblasts, or by promoting the production of collagen, elastin, and hyaluronic acid by the differentiation of fibroblasts.
  • composition according to the present disclosure For skin aging prevention, for example, when the composition according to the present disclosure is applied to human skin once to three times a day for 3 weeks, as compared with the case where the composition according to the present disclosure is not applied.
  • the elasticity of the skin may be maintained or improved by 5% or more, 10% or more or 15% or more.
  • Wound healing means that wound healing is promoted. Wound healing can be achieved by increased expression of CCN1 and CCN2, accelerated proliferation of fibroblasts, or migration and proliferation of epidermal cells. Wound healing is enhanced, for example, when the composition according to the present disclosure is applied to a wound on the skin, as compared to when the composition according to the present disclosure is not applied to a wound on the same degree of skin. It may be that.
  • “Promoting hair growth” means promoting hair growth. Hair promotion can be achieved by increasing the expression of CCN1 and CCN2, promoting the differentiation of hair follicle stem cells into hair papilla cells, or promoting the proliferation of hair follicle stem cells and / or hair papilla cells. The promotion of hair growth may be, for example, when the composition according to the present disclosure is applied to the scalp, the hair on the scalp is increased as compared with the case before the composition according to the present disclosure is applied.
  • the skin-applied composition according to the present disclosure is for skin aging prevention, wound healing, or hair growth promotion, preferably for skin aging prevention or wound healing, and more preferably. It is for preventing skin aging.
  • RT-PCR was performed using One Step TB Green (registered trademark) PrimeScript (trademark) RT-PCR Kit according to the instructions attached to the kit.
  • RT-PCR of CCN1 primers having each nucleic acid sequence shown in SEQ ID NOs: 1 and 2 were used.
  • RT-PCR of CCN2 primers having each nucleic acid sequence shown in SEQ ID NOs: 3 and 4 were used.
  • FIG. 1 shows the plant sample No. 1 to No. 3 and No. 5 shows that the expression level of CCN1 was increased as compared with the control C1.
  • FIG. 2 shows the plant sample No. 1 and No. 3 to No. 8 shows that the expression level of CCN1 was increased as compared with the control C2.
  • 1 and 2 show the plant sample No. 1, No. 3 and No. 5 showed that both the water extract and the 70% ethanol extract increased the expression level of CCN1 as compared with the controls C1 and C2, respectively.
  • 1 and 2 also show the plant sample No. 2 shows that in the case of a water extract, the expression of CCN1 is increased, but in the case of a 70% ethanol extract, the expression of CCN1 is decreased.
  • FIG. 3 shows the plant sample No. 2.
  • No. 3 and No. 8 shows that the expression level of CCN2 was increased as compared with the control C1.
  • FIG. 4 shows the plant sample No. 1 indicates that the expression level of CCN2 was increased as compared with the control C2.
  • 3 and 4 show the plant sample No. 2.
  • No. 3 and No. 8 shows that in the case of a water extract, the expression of CCN2 is increased, but in the case of a 70% ethanol extract, the expression of CCN2 is decreased.
  • FIGS. 1 to 4 show No. 2 and No. It is shown that the water extract of No. 3 increased the expression level of CCN1 and CCN2, respectively, as compared with the controls C1 and C2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Immunology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne une nouvelle composition à appliquer sur la peau pour augmenter l'expression de CCN1 et CCN2.　Cette composition à appliquer sur la peau est utilisée pour augmenter l'expression de CCN1 et CCN2, et contient soit un extrait de Clitoria ternatea dans de l'eau ou moins de 10 % d'alcool, soit un extrait de Pandanus amaryllifolius dans de l'eau ou moins de 10 % d'alcool, ou les deux.
PCT/JP2021/024386 2020-06-29 2021-06-28 Composition à appliquer sur la peau pour augmenter l'expression de ccn1 et ccn2 WO2022004669A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020-111472 2020-06-29
JP2020111472A JP6978015B1 (ja) 2020-06-29 2020-06-29 Ｃｃｎ１及びｃｃｎ２の発現を増加させるための皮膚適用用組成物

Publications (1)

Publication Number Publication Date
WO2022004669A1 true WO2022004669A1 (fr) 2022-01-06

Family

ID=78815542

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/024386 WO2022004669A1 (fr) 2020-06-29 2021-06-28 Composition à appliquer sur la peau pour augmenter l'expression de ccn1 et ccn2

Country Status (2)

Country Link
JP (1) JP6978015B1 (fr)
WO (1) WO2022004669A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024057970A1 (fr) * 2022-09-14 2024-03-21 株式会社 資生堂 Composition comprenant un extrait de thé vert, pour favoriser l'expression de ccn2

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004043393A (ja) * 2002-07-15 2004-02-12 Noevir Co Ltd 血管内皮細胞増殖因子産生促進剤
JP2007016003A (ja) * 2005-07-11 2007-01-25 Toyo Ink Mfg Co Ltd 抗酸化剤
JP2008162897A (ja) * 2006-12-27 2008-07-17 Toyo Ink Mfg Co Ltd 頭髪外用剤
CN108578294A (zh) * 2018-06-17 2018-09-28 佛山文森特知识产权服务有限公司 一种促进皮肤提升效果和保湿功效的护肤组合物和化妆品

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4445658B2 (ja) * 2000-10-12 2010-04-07 共栄化学工業株式会社 化粧料
JP3591832B2 (ja) * 2002-03-14 2004-11-24 株式会社ノエビア 皮膚外用剤
JP2004043392A (ja) * 2002-07-15 2004-02-12 Noevir Co Ltd 頭皮頭髪用外用剤
WO2010108488A2 (fr) * 2009-03-27 2010-09-30 Evoria Gmbh Extraits de plantes pour le traitement de maladies de la peau
WO2011087654A1 (fr) * 2009-12-22 2011-07-21 Avon Products, Inc. Compositions stimulant la paxilline et leurs utilisations cosmétiques

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004043393A (ja) * 2002-07-15 2004-02-12 Noevir Co Ltd 血管内皮細胞増殖因子産生促進剤
JP2007016003A (ja) * 2005-07-11 2007-01-25 Toyo Ink Mfg Co Ltd 抗酸化剤
JP2008162897A (ja) * 2006-12-27 2008-07-17 Toyo Ink Mfg Co Ltd 頭髪外用剤
CN108578294A (zh) * 2018-06-17 2018-09-28 佛山文森特知识产权服务有限公司 一种促进皮肤提升效果和保湿功效的护肤组合物和化妆品

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024057970A1 (fr) * 2022-09-14 2024-03-21 株式会社 資生堂 Composition comprenant un extrait de thé vert, pour favoriser l'expression de ccn2

Also Published As

Publication number Publication date
JP6978015B1 (ja) 2021-12-08
JP2022022590A (ja) 2022-02-07

Similar Documents

Publication Publication Date Title
JP6765170B2 (ja) 脱分化植物細胞の化粧的使用
KR101844598B1 (ko) 화장품 조성물
KR102294818B1 (ko) 불가사리 추출물을 유효성분으로 포함하는 피부 재생 및 피부 보습용 조성물
KR101850648B1 (ko) 피부보습 및 재생 촉진활성을 갖는 녹차유래의 다당체를 함유하는 화장료 조성물 및 그 제조방법
US20070224139A1 (en) Cosmetic compositions
KR102113645B1 (ko) 미세침 분말 및 천연 추출물을 유효성분으로 포함하는 탈모 방지 및 모발 성장 촉진용 화장료 조성물
KR101687353B1 (ko) 오죽 추출물을 함유하는 피부 온도 조절용 화장료 조성물
WO2022004669A1 (fr) Composition à appliquer sur la peau pour augmenter l'expression de ccn1 et ccn2
KR102413205B1 (ko) 자소엽, 유칼립투스 유래 엑소좀을 유효성분으로 함유하는 보습, 피부진정, 항염, 세포재생 및 주름개선용 화장료 조성물
KR101124971B1 (ko) 함초캘러스 추출물 및 라미나리아 디지타타추출물을 함유하는 피부주름개선또는 피부탄력증진용 화장료 조성물
KR101946880B1 (ko) 소목 추출물을 유효성분으로 함유하는 피부 장벽기능 강화용 화장료 조성물 및 피부보습제
US20230390234A1 (en) Composition inhibiting muscle loss or promoting muscle formation through skin-derived exosomes
KR101798632B1 (ko) 피뿌리풀 추출물 또는 그의 분획물을 포함하는 화장 조성물 및 그의 용도
KR101872357B1 (ko) 짝자래나무 추출물을 함유하는 피부 탄력 증진용 화장료 조성물
KR102508159B1 (ko) 비버눔 스텔라토토멘토섬 추출물을 포함하는 피부 노화 방지 및 피부 주름 개선용 화장료 조성물
KR101679391B1 (ko) 피뿌리풀 추출물 또는 그의 분획물을 포함하는 상처를 치료하기 위한 조성물 및 개체의 상처를 치료하는 방법
KR101597762B1 (ko) 피뿌리뿔 추출물 또는 그의 분획물을 포함하는 상처를 치료하기 위한 조성물 및 개체의 상처를 치료하는 방법
KR101944494B1 (ko) 털마삭줄을 포함하는 마삭줄속 식물 추출물을 유효성분으로 함유하는 화장료 조성물
JP6901256B2 (ja) 上皮細胞賦活剤
KR101865688B1 (ko) 털마삭줄 추출물, 황련 추출물 및 회화나무 추출물을 유효성분으로 함유하는 화장료 조성물
KR100855456B1 (ko) 삼지구엽초를 유효성분으로 함유하는 모공수축용 화장료조성물
KR102385111B1 (ko) 갈란가 및 배더락스 복합추출물을 유효성분으로 함유하는 화장료 조성물
KR102248170B1 (ko) 참다래 줄기 추출물을 유효성분으로 함유하는 피부 재생 또는 상처 치유용 조성물
CN115261309B (zh) 促进细胞增殖的方法及包含细胞因子的化妆品或药物
JP6904688B2 (ja) 上皮細胞賦活剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21832679

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21832679

Country of ref document: EP

Kind code of ref document: A1